Spruce Capital Partners

The firm focuses on venture-stage companies that apply advanced biology, data science, and digital tools to agriculture, nutrition, and industrial life sciences. Its portfolio spans engineered microbes, gene-editing platforms, crop coatings, and spectroscopic phenotyping — technologies that aim to improve crop yields, reduce chemical inputs, and enhance nutritional density across the food supply chain.

The firm's disclosed positions include Pivot Bio, which commercialized nitrogen-fixing microbes to replace synthetic fertilizer; Inscripta, which developed an automated CRISPR platform for microbial engineering; and Provivi, which makes insect pheromones for pesticide-free crop protection. Additional disclosed holdings include Consumer Physics, Crop Enhancement, GreenLight Biosciences, Evolve BioSystems, Amfora, and AGERpoint (per the firm's website).

The firm acts as a direct venture capital manager investing its commingled funds into portfolio companies. Its website indicates the managing partners have made investments together across multiple funds for more than a decade, but the firm does not publicly disclose fund names, vintages, or close sizes.

Spruce Capital Partners operates as an independent venture capital firm headquartered in San Francisco. It is not a corporate venture arm of a larger agribusiness or pharmaceutical company, and there is no publicly disclosed parent entity steering its investment decisions.

No. The firm does not disclose assets under management, fund sizes, or total deployment figures in publicly available sources. Any AUM figure would be an Altss estimate, which is not available for this profile.